Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;76(5):e13002.
doi: 10.1111/jpi.13002.

Relationship Between Melatonin Receptor Agonists and Parkinson's Disease

Yoshihiro Noguchi  1 , Rikuto Masuda  1 , Haruka Aizawa  1 , Tomoaki Yoshimura  1
Affiliations

Relationship Between Melatonin Receptor Agonists and Parkinson's Disease

Yoshihiro Noguchi et al. J Pineal Res. 2024 Aug.

Abstract

Parkinson's disease affects millions of people worldwide, and without significant progress in disease prevention and treatment, its incidence and prevalence could increase by more than 30% by 2030. Researchers have focused on targeting sleep and the circadian system as a novel treatment strategy for Parkinson's disease. This study investigated the association between melatonin receptor agonists and Parkinson's disease, using the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS). The target drugs were melatonin receptor agonists including ramelteon, tasimelteon, and agomelatine. Parkinson's disease cases were defined according to the Medical Dictionary for Regulatory Activities (MedDRA) 25.0; Standardized MedDRA Query (SMQ) using both the "narrow" and "broad" preferred terms (PTs) associated with Parkinson's disease. The association between melatonin receptor agonists (ramelteon, tasimelteon, and agomelatine) and Parkinson's disease was evaluated by the reporting odds ratio. Upon analyzing the data from all patients registered in the FAERS, ramelteon (ROR: 0.66, 95% confidence interval [95% CI]: 0.51-0.84) and tasimelteon (ROR: 0.49, 95% CI: 0.38-0.62) showed negative correlations with Parkinson's disease. Conversely, only agomelatine was positively correlated with Parkinson's disease (ROR: 2.63, 95% CI: 2.04-3.40). These results suggest that among the melatonin receptor agonists, ramelteon and tasimelteon are negatively correlated with Parkinson's disease. In contrast, agomelatine was shown to be positively correlated with Parkinson's disease. These results should be used in research to develop drugs for the treatment of Parkinson's disease, fully considering the limitations of the spontaneous reporting system.

Keywords: Parkinson's disease; melatonin receptor agonists; pharmacovigilance database; reporting odds ratio.

PubMed Disclaimer

References

    1. A. Elbaz and F. Moisan, “Update in the Epidemiology of Parkinson's Disease,” Current Opinion in Neurology 21 (2008): 454–460, https://doi.org/10.1097/WCO.0b013e3283050461.
    1. Z. Zhang, G. Roman, Z. Hong, et al., “Parkinson's Disease in China: Prevalence in Beijing, Xian, and Shanghai,” Lancet 365 (2005): 595–597, https://doi.org/10.1016/S0140-6736(05)17909-4.
    1. T. K. Khoo, A. J. Yarnall, G. W. Duncan, et al., “The Spectrum of Nonmotor Symptoms in Early Parkinson Disease,” Neurology 80 (2013): 276–281, https://doi.org/10.1212/WNL.0b013e31827deb74.
    1. L. Lopiano, N. Modugno, P. Marano, et al., “Motor Outcomes in Patients With Advanced Parkinson's Disease Treated With Levodopa/Carbidopa Intestinal Gel in Italy: An Interim Analysis From the GREENFIELD Observational Study,” Neurological Sciences 37 (2016): 1785–1792, https://doi.org/10.1007/s10072-016-2664-0.
    1. J. M. Beitz, “Parkinson's Disease: A Review,” Frontiers in Bioscience 6 (2014): 65–74, https://doi.org/10.2741/s415.

LinkOut - more resources